Imdevimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Imdevimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Imdevimab can convert its Monoclonal antibody profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Imdevimab (query alias: Imdevimab) |
|---|---|
| Modality / target | Monoclonal antibody; SARS-CoV-2 S protein; SARS-CoV-2 S protein inhibitors |
| Highest global status | Approved |
| Originator | Regeneron Pharmaceuticals, Inc. |
| Active developers | Roche Products Ltd. |
The MCP disease footprint includes COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| EUCTR2021-004188-28-IT | Phase 4 | Not Recruiting | 1550 | A composite endpoint of either severe COVID-19 or hospitalization or access in an emergency department or death from any cause by day 29 after randomization. Severe COVID-19 is characterized by a minimum of either pneumonia (fever, cough, tachypnea, or dyspnea, AND lung infiltrates) and hypoxemia (SpO2 < 92% in room air and/or severe respiratory distress) and a WHO Clinical Progression Scale score of 5 or higher |
| NCT05502081 | Phase 4 | Completed | 265 | 28-days Mortality Rate |
| NCT05081388 | Phase 1/2 | Terminated | 25 | Treatment Emergent Adverse Events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease
Phase 1/2; n=25; evaluation: not stated. Reported fields: TEAE = 1 Events ; -; -
The UPMC OPtimizing Treatment and Impact of Monocolonal antIbodieS Through Evaluation for COVID-19 Trial
Phase 4; n=4571; evaluation: not stated. Reported fields: -; Hospital-free Days(Median) = 28 days (Inter-Quartile Range, 28 - 28); Hospital-free Days(Median) = 28 days (Inter-Quartile Range, 28 - 28)
Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (Casirivimab and Imdevimab) Versus Standard Antiviral Therapy (Remdesivir and Favipravir) as Antiviral Agent Against Corona Virus 2 Infection in Hospitalized COVID-19 Patients
Phase 4; n=265; evaluation: not stated. Reported fields: 28-days Mortality Rate: P-Value = <0.001; P-Value = 0.176; P-Value = <0.001; P-Value = <0.001; 28-days Mortality Rate: P-Value = <0.001; P-Value = 0.176; P-Value = <0.001; P-Value = <0.001; 28-days Mortality Rate: P-Value = <0.001; P-Value = 0.176; P-Value = <0.001; P-Value = <0.001
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Imdevimab addresses COVID-19. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 178 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SARS-CoV-2 S protein records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-02-11 | Moderna transfer its Covid-19 vaccine technology to Mexican pharma company Liomont. | Approved | Financial terms not disclosed |
| 2026-01-21 | Karolinska Development’s portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin | Phase 2 | Financial terms not disclosed |
| 2025-09-04 | HK inno.N and Pfizer Korea sign COVID-19 vaccine distribution agreement | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
